CY1119122T1 - Θεραπευτικη αναπληρωση και εμπλουτισμος της λιπανσεως της οφθαλμικης επιφανειας - Google Patents

Θεραπευτικη αναπληρωση και εμπλουτισμος της λιπανσεως της οφθαλμικης επιφανειας

Info

Publication number
CY1119122T1
CY1119122T1 CY20171100751T CY171100751T CY1119122T1 CY 1119122 T1 CY1119122 T1 CY 1119122T1 CY 20171100751 T CY20171100751 T CY 20171100751T CY 171100751 T CY171100751 T CY 171100751T CY 1119122 T1 CY1119122 T1 CY 1119122T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
hyaluronic acid
present
ophthalmically acceptable
lubrication
Prior art date
Application number
CY20171100751T
Other languages
English (en)
Inventor
Benjamin Sullivan
Tannin A Schmidt
David A Sullivan
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of CY1119122T1 publication Critical patent/CY1119122T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Eyeglasses (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μία φαρμακευτική σύνθεση, και μεθόδους χρήσεως αυτής, για την αγωγή της οφθαλμικής οριακής ανεπάρκειας, των συμπτωμάτων που σχετίζονται με αυτήν, ή ανεπιθύμητης καταστάσεως που σχετίζεται με την οφθαλμική οριακή ανεπάρκεια στην οφθαλμική επιφάνεια ή την προκαλεί. Η φαρμακευτική σύνθεση της παρούσας εφευρέσεως περιλαμβάνει μία ανθρώπινη πρωτεΐνη PRG4, ένα λιπαντικό θραύσμα, ομόλογο, ή ισόμορφη αυτής, σε εναιώρηση εντός ενός οφθαλμικά αποδεκτού ισορροπημένου διαλύματος αλάτων. Η φαρμακευτική σύνθεση της παρούσας εφευρέσεως μπορεί επίσης να περιλαμβάνει έναν ή περισσότερους οφθαλμικά αποδεκτούς παράγοντες επιλεγόμενους από την ομάδα που αποτελείται από ένα οφθαλμικά αποδεκτό καταπραϋντικό, έκδοχο, στυπτικό, αγγειοσυσταλτικό, μαλακτικό, υαλουρονικό νάτριο, υαλουρονικό οξύ, και επιφανειοδραστικά φωσφολιπίδια, εντός ενός φαρμακευτικά αποδεκτού φορέα για τοπική χορήγηση.
CY20171100751T 2008-05-07 2017-07-14 Θεραπευτικη αναπληρωση και εμπλουτισμος της λιπανσεως της οφθαλμικης επιφανειας CY1119122T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5111208P 2008-05-07 2008-05-07
EP09743204.1A EP2285364B1 (en) 2008-05-07 2009-04-08 Therapeutic replenishment and enrichment of ocular surface lubrication

Publications (1)

Publication Number Publication Date
CY1119122T1 true CY1119122T1 (el) 2018-02-14

Family

ID=41264988

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100751T CY1119122T1 (el) 2008-05-07 2017-07-14 Θεραπευτικη αναπληρωση και εμπλουτισμος της λιπανσεως της οφθαλμικης επιφανειας
CY20191101037T CY1122638T1 (el) 2008-05-07 2019-10-03 Θεραπευτικη διαφοροποιηση της λιπανσης της οφθαλμικης επιφανειας

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20191101037T CY1122638T1 (el) 2008-05-07 2019-10-03 Θεραπευτικη διαφοροποιηση της λιπανσης της οφθαλμικης επιφανειας

Country Status (16)

Country Link
US (9) US9138457B2 (el)
EP (4) EP2915529B1 (el)
JP (3) JP5508398B2 (el)
CN (2) CN102164593B (el)
CA (3) CA2722913C (el)
CY (2) CY1119122T1 (el)
DK (3) DK2285364T3 (el)
ES (3) ES2530723T3 (el)
HR (3) HRP20150097T1 (el)
HU (2) HUE024146T2 (el)
LT (2) LT2915529T (el)
PL (3) PL2915529T3 (el)
PT (2) PT2915529T (el)
RU (1) RU2510274C2 (el)
SI (3) SI2915529T1 (el)
WO (3) WO2009137217A2 (el)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US8083787B2 (en) 2005-07-18 2011-12-27 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction
US7981146B2 (en) 2006-05-15 2011-07-19 Tearscience Inc. Inner eyelid treatment for treating meibomian gland dysfunction
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US20090043365A1 (en) 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US7981095B2 (en) * 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8128673B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7981147B2 (en) 2006-05-15 2011-07-19 Tearscience, Inc. Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8137390B2 (en) 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US8128674B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8007524B2 (en) 2006-05-15 2011-08-30 Tearscience, Inc. Heat treatment and heat loss reduction for treating meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US7976573B2 (en) 2006-05-15 2011-07-12 Tearscience, Inc. Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US8506944B2 (en) 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
JP5508398B2 (ja) * 2008-05-07 2014-05-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼の表面潤滑の治療的補充及び強化
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
CA2762989C (en) 2009-05-22 2021-04-13 Benjamin Sullivan Prg4 for treatment of oral cavity boundary lubrication disorders
KR20120115380A (ko) * 2010-01-11 2012-10-17 지티엑스, 인코포레이티드 마이봄선 기능 장애의 치료 방법
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
US9764009B2 (en) * 2011-06-13 2017-09-19 Allergan, Inc. Treatment of psychological trauma
JP2014522849A (ja) * 2011-06-29 2014-09-08 アラーガン インコーポレイテッド ヒドロキシステアリン酸マクロゴール１５製剤
US20130029919A1 (en) 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
US20140309400A1 (en) * 2011-11-30 2014-10-16 Xigen Inflammation Ltd. Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Dry Eye Syndrome
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US9827250B2 (en) * 2012-07-31 2017-11-28 Johnson & Johnson Vision Care, Inc. Lens incorporating myopia control optics and muscarinic agents
WO2014031857A2 (en) 2012-08-22 2014-02-27 Tearscience, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
US9763827B2 (en) 2013-04-30 2017-09-19 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
ES2821002T3 (es) 2013-04-30 2021-04-23 Alcon Inc Sistemas para el tratamiento de enfermedades del ojo
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
CA2903275A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015060935A1 (en) 2013-10-22 2015-04-30 Lubris, Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
US9668916B2 (en) 2013-11-04 2017-06-06 Vance M. Thompson Conjunctival cover and methods therefor
US20150141328A1 (en) * 2013-11-18 2015-05-21 The Schepens Eye Research Institute Stimulation of human meibomian gland function
EP4062924A1 (en) 2013-11-26 2022-09-28 Lubris LLC Compositions and methods for inhibiting intercellular interactions
EP3154550B1 (en) 2014-06-15 2021-08-04 Yeda Research and Development Co. Ltd. Surface treatment by water-soluble polymers and lipids/liposomes
IL234929B (en) * 2014-10-01 2021-01-31 Yeda Res & Dev Preparations containing liposomes and their use to prevent infections
US9395557B2 (en) 2014-11-12 2016-07-19 Vance M. Thompson Partial corneal conjunctival contact lens
ES2808199T3 (es) * 2015-01-26 2021-02-25 Lubris Llc Uso de PRG4 como un agente antiinflamatorio
US9869883B2 (en) 2015-03-11 2018-01-16 Vance M. Thompson Tear shaping for refractive correction
MX2017012708A (es) * 2015-04-03 2018-01-09 Santen Pharmaceutical Co Ltd Agente terapeutico para ojo seco que comprende nandrolona o ester del mismo o metenolona o ester del mismo como un ingrediente activo.
HUE056409T2 (hu) * 2015-05-19 2022-02-28 Lubris Llc PRG4 alkalmazása dinamikus látásélesség és magasabb rendû aberrációk javítására
JP6718608B2 (ja) * 2016-05-25 2020-07-08 国立大学法人愛媛大学 眼表面・眼瞼摩擦係数測定装置および眼表面・眼瞼摩擦係数評価方法
US10974063B2 (en) 2016-06-30 2021-04-13 Alcon Inc. Light therapy for eyelash growth
US10353220B2 (en) 2016-10-17 2019-07-16 Vance M. Thompson Tear shaping for refractive correction
US10678067B2 (en) 2018-04-06 2020-06-09 Vance M. Thompson Tear shaping for refractive correction
JP2021527645A (ja) * 2018-06-21 2021-10-14 ルブリス，エルエルシー． 創傷治癒での使用のためのラブリシン
WO2020097345A1 (en) * 2018-11-08 2020-05-14 The Schepens Eye Research Institute, Inc. Therapeutic approaches for tissue reconstruction and wound healing treatment
WO2020150390A1 (en) * 2019-01-15 2020-07-23 Cornell University Recombinant mucins, and compositions and methods for using the same
EP4003225A4 (en) * 2019-07-26 2023-05-31 Pandorum Technologies Private Limited BIOLOGICAL INK FORMULATIONS, BIO-PRINTED LENTICULUS AND RELATED APPLICATIONS
US20220347167A1 (en) * 2019-10-05 2022-11-03 The Schepens Eye Research Institute, Inc. A new treatment for meibomian gland dysfunction
US11609438B2 (en) * 2019-10-31 2023-03-21 Menicon Singapore Pte Ltd. Ocular lens with friction control structures

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550022A (en) * 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
SE8501723L (sv) 1985-04-09 1986-10-10 Pharmacia Ab Preparation att anvendas vid behandling av ledinflammation
US4964206A (en) * 1988-03-15 1990-10-23 Minnesota Mining And Manufacturing Company Intraocular lens anchoring filament to lens element fixation method
US4964205A (en) * 1988-06-13 1990-10-23 Rampart Packaging Inc. Method for making screw cap jar
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
US6433142B1 (en) 1989-08-08 2002-08-13 Genetics Institute, Llc Megakaryocyte stimulating factors
RU2033165C1 (ru) * 1989-10-13 1995-04-20 Межотраслевой научно-технический комплекс "Микрохирургия глаза" Способ получения пластичного материала из коллагена
CA2133966C (en) 1992-04-21 1997-09-09 David A. Sullivan Ocular androgen therapy in sjogren's syndrome
US5688765A (en) 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
IL106922A (en) * 1992-09-14 1998-08-16 Novartis Ag Complex materials with one or more wettable surfaces and a process for their preparation
US5351100A (en) * 1992-12-09 1994-09-27 Bmc Industries, Inc. Glass multifocal ophthalmic lens with polarizing element and method of making
DE69434617D1 (de) * 1993-11-19 2006-04-06 Univ Sydney Verfahren zur prophylaxe oder kontrolle des katarakts
US5515590A (en) * 1994-07-19 1996-05-14 University Of Kentucky Research Foundation Method for reducing the generation of wear particulates from an implant
US5518732A (en) * 1995-02-14 1996-05-21 Chiron Vision, Inc. Bio-erodible ophthalmic shield
EP0733918B1 (en) * 1995-03-24 2003-07-30 Ocular Research of Boston, Inc. Hydrogel lens pre-coated with lipid layer
RU2207885C2 (ru) * 1995-08-30 2003-07-10 Фармация Аб Способ подачи небольшого объема лечебного раствора к целевому месту
US6689748B1 (en) * 1998-04-08 2004-02-10 Theoharis C. Theoharides Method of treating mast cell activation-induced diseases with a proteoglycan
AU1521000A (en) * 1998-11-06 2000-05-29 Schepens Eye Research Institute, Inc., The Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye
CN1157191C (zh) * 1998-11-10 2004-07-14 电气化学工业株式会社 透明质酸凝胶、其制造方法及含透明质酸凝胶的医用材料
US6743774B1 (en) 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
US6960562B2 (en) 1999-04-23 2005-11-01 Rhode Island Hospital, A Lifespan Partner Tribonectin polypeptides and uses thereof
JP4755795B2 (ja) * 2000-02-03 2011-08-24 電気化学工業株式会社 ヒアルロン酸ゲルの製造方法及びそれを含有する医用材料
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US6919321B2 (en) * 2000-12-20 2005-07-19 Alcon, Inc. Ophthalmic lubricating solution adapted for use in lasik surgery
CA2431368C (en) * 2000-12-20 2006-08-08 Alcon, Inc. Intraocular irrigating solution having improved flow characteristics
ES2261659T3 (es) * 2001-04-23 2006-11-16 Nucryst Pharmaceuticals Corp. Un medicamento o una preparacion que contiene un metal tal como plata, oro, platino o paladio como un agente antimicrobiano y su uso para el tratamiento de estados inflamatorios de la piel.
US6815074B2 (en) 2001-05-30 2004-11-09 Novartis Ag Polymeric materials for making contact lenses
CN1980582B (zh) * 2001-08-17 2010-12-22 美你康株式会社 用于用后即弃式软隐形眼镜的包装
US20030134810A1 (en) 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
TWI255224B (en) * 2002-01-09 2006-05-21 Novartis Ag Polymeric articles having a lubricious coating and method for making the same
AR038926A1 (es) 2002-03-13 2005-02-02 Novartis Ag Materiales con contenido de multiples capas de vesiculas
SE0201479D0 (sv) * 2002-05-16 2002-05-16 Pharmacia Groningen Bv Kit and method in eye surgery
US20050196370A1 (en) 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
US20050074497A1 (en) 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
MXPA06001401A (es) 2003-08-06 2006-05-19 Nirmal Mulye Composicion farmaceutica que contiene farmaco soluble en agua.
CN102924584A (zh) 2003-08-14 2013-02-13 惠氏公司 重组润滑素分子及其用途
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
WO2005027933A1 (en) 2003-09-23 2005-03-31 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Unsaturated phosphatidylcholines and uses thereof
US20070275032A1 (en) * 2004-03-05 2007-11-29 Synthes (U.S.A.) Use Of A Mixture For The Production Of An Agent For Treating Defective Or Degenerated Cartilage In The Production Of Natural Cartilage Replacement In Vitro
US20090060933A1 (en) 2004-06-14 2009-03-05 Estell David A Proteases producing an altered immunogenic response and methods of making and using the same
US20050287223A1 (en) * 2004-06-23 2005-12-29 Peyman Gholam A Use of amniotic membrane as biocompatible devices
WO2006088491A2 (en) * 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
US20080287369A1 (en) * 2004-07-23 2008-11-20 Jay Gregory D Compositions and Methods for Viscosupplementation
US7662509B2 (en) * 2004-10-29 2010-02-16 Medtronic, Inc. Lithium-ion battery
AU2006218653A1 (en) * 2005-03-02 2006-09-08 Barnett, Gene Ph.D. Pharmaceutically acceptable carrier for ophthalmic compositions
DK2444079T3 (en) * 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
JP5549045B2 (ja) * 2006-01-13 2014-07-16 大正製薬株式会社 蒸発亢進型ドライアイの予防又は改善用水性点眼剤
US20080094573A1 (en) 2006-04-04 2008-04-24 Vermette Patrick Surface-modified materials, such as contact lenses, methods and kits for their preparation, and uses thereof
US9539202B2 (en) * 2006-04-28 2017-01-10 Universidad Complutense De Madrid Formulation of liposomal vesicles in aqueous solutions with lachrymal film characteristics
US20070264226A1 (en) * 2006-05-10 2007-11-15 Karagoezian Hampar L Synergistically enhanced disinfecting solutions
ES2581765T3 (es) * 2006-08-24 2016-09-07 University Of Tennessee Research Foundation Acilanilidas sustituidas y métodos de uso de las mismas
US20080097606A1 (en) 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
US20080197324A1 (en) * 2007-02-20 2008-08-21 Fang Zhao Ophthalmic composition containing a polyol-acid copolymer
US20090068247A1 (en) 2007-09-12 2009-03-12 Mucosal Therapeutics Biocompatible devices coated with a tribonectin and methods for their production
AU2008343162B2 (en) 2007-12-20 2012-02-23 Alcon Inc. Method for making contact lenses
US8506944B2 (en) * 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
JP5508398B2 (ja) * 2008-05-07 2014-05-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼の表面潤滑の治療的補充及び強化

Also Published As

Publication number Publication date
ES2530723T3 (es) 2015-03-04
LT2276496T (lt) 2019-10-25
JP5508398B2 (ja) 2014-05-28
EP2276496B1 (en) 2019-07-10
US20110070222A1 (en) 2011-03-24
HRP20171079T1 (hr) 2017-10-06
LT2915529T (lt) 2018-10-25
ES2633792T3 (es) 2017-09-25
CN102164593B (zh) 2016-02-03
HUE045686T2 (hu) 2020-01-28
WO2009137602A1 (en) 2009-11-12
US9730978B2 (en) 2017-08-15
EP2276497A4 (en) 2011-12-21
ES2748139T3 (es) 2020-03-13
SI2915529T1 (sl) 2017-09-29
EP2276496A4 (en) 2011-08-17
EP2276496A1 (en) 2011-01-26
HRP20150097T1 (hr) 2015-03-27
DK2276496T3 (da) 2019-10-07
EP2915529B1 (en) 2017-06-14
HUE024146T2 (en) 2016-02-29
US20180028598A1 (en) 2018-02-01
JP5439652B2 (ja) 2014-03-12
CN105664136A (zh) 2016-06-15
PL2276496T3 (pl) 2020-01-31
JP2011520812A (ja) 2011-07-21
US20160101149A1 (en) 2016-04-14
RU2510274C2 (ru) 2014-03-27
WO2009137217A2 (en) 2009-11-12
US9138457B2 (en) 2015-09-22
SI2285364T1 (sl) 2015-03-31
CA2722913A1 (en) 2009-11-12
US8945604B2 (en) 2015-02-03
SI2276496T1 (sl) 2019-11-29
CA2723144A1 (en) 2009-11-12
PT2915529T (pt) 2017-07-24
WO2009137217A8 (en) 2010-12-09
PT2285364E (pt) 2015-02-24
US20110059902A1 (en) 2011-03-10
US9248161B2 (en) 2016-02-02
US20160235809A1 (en) 2016-08-18
DK2285364T3 (en) 2015-02-16
EP2276497B1 (en) 2020-04-22
JP2011519933A (ja) 2011-07-14
US8563028B2 (en) 2013-10-22
US20140296159A1 (en) 2014-10-02
WO2009137217A3 (en) 2009-12-30
US20140099343A1 (en) 2014-04-10
DK2915529T3 (en) 2017-08-07
US9421241B2 (en) 2016-08-23
PL2915529T3 (pl) 2017-10-31
EP2285364B1 (en) 2015-01-21
JP2011519949A (ja) 2011-07-14
CA2723144C (en) 2018-05-22
EP2285364A4 (en) 2011-07-20
WO2009137603A1 (en) 2009-11-12
JP5474054B2 (ja) 2014-04-16
EP2285364A2 (en) 2011-02-23
RU2010147935A (ru) 2012-06-20
EP2276497A1 (en) 2011-01-26
US9393285B2 (en) 2016-07-19
US9585936B2 (en) 2017-03-07
EP2915529A1 (en) 2015-09-09
HRP20191732T1 (hr) 2019-12-13
CA2722913C (en) 2018-02-27
CA2722944A1 (en) 2009-11-12
CY1122638T1 (el) 2021-03-12
PL2285364T3 (pl) 2015-04-30
CN102164593A (zh) 2011-08-24
US20110142908A1 (en) 2011-06-16
US20160015780A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
CY1119122T1 (el) Θεραπευτικη αναπληρωση και εμπλουτισμος της λιπανσεως της οφθαλμικης επιφανειας
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
EA200901211A1 (ru) Антигены белка с5 и их применение
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
CO6390109A2 (es) Inhibidores de syk de imidazopirazina
EA201300213A1 (ru) Применение ингибиторов dpp iv
AR071732A1 (es) Metodos para tratar la enfermedad de alzheimer, reducir la disminucion del volumen cerebral y monitorear una poblacion de pacientes que experimentan tratamiento o profilaxis para una enfermedad, uso de una medida de numero de copia apoe4, forma humanizada de un anticuerpo y acido nucleico aislado.
BR112014019776A2 (pt) composições e métodos para o tratamento de doença vascular periférica
CO6341486A2 (es) Tratamiento y profilaxis de amiloidosis
BR112014006376A2 (pt) terapia baseada em proteínas e diagnóstico de patologia mediada por tau em doença de alzheimer
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
BR112015001419A2 (pt) composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
EA200870396A1 (ru) Лечение аллергических заболеваний глаз
CY1110435T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια οφθαλμικων καταστασεων με παραγωγα ρετινολης
BR112013017446A2 (pt) composição, uso de dose baixa de pioglitazona, método de tratar a deterioração cognitiva do tipo de alzheimer em um indivíduo humano, de tratar o declínio cognitivo em um indivíduo humano, de determinar o risco aumentado de desenvolver a deterioração cognitiva do tipo de alzheimer em um indivíduo humano em uma uma idade ou faixa de idade pré-determinadas, de determinar se administrar dose baixa de pioglitazona a um indivíduo humano para o tratamento da deterioração congnitiva do tipo de alzheimer, de retardar o início da doença de alzheimer em um indivíduo em risco de desenvolver a doença alzheimer, de retardar o início da deterioração cognitiva amnésia branda em um indivíduo em risco de desenvolver a doença de alzheimer, de retardar o início da doença de alzheimer pré-clínica em um indivíduo em risco de desenvolver a doença de alzheimer, de retardar o início da doença de alzheimer pródroma em um indivíduo em risco de desenvolver a doença de alzheimer, dose baixa de pioglitazona
EA201790653A1 (ru) Способ лечения болезни альцгеймера и других расстройств
AR080026A1 (es) Metodos de tratamiento de enfermedades autoinmunitarias con antagonistas del ligando 4 similar a delta (dll4)
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
BR112016028446A2 (pt) inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
CY1117854T1 (el) Πεπτιδικη φαρμακοτεχνικη μορφη για τοπικη οφθαλμικη χρηση